Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry

Ketty Peris

doi:10.1016/j.jaad.2013.10.019

Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry

Ketty Peris

Risultato della ricerca: Contributo in rivista › Articolo

46 Citazioni (Scopus)

Abstract

Some studies have shown that switching patients from one tumor necrosis factor (TNF)-alfa inhibitor to another may be beneficial when they have an inadequate response or an adverse event.

Lingua originale	Inglese
pagine (da-a)	257-257-62.e3
Rivista	Journal of the American Academy of Dermatology
Volume	70
DOI	https://doi.org/10.1016/j.jaad.2013.10.019
Stato di pubblicazione	Pubblicato - 2014

Keywords

75% improvement in the Psoriasis Area Severity Index score
Adult
Analysis of Variance
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Cohort Studies
Confidence Intervals
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Immunoglobulin G
Italy
Male
Middle Aged
Multivariate Analysis
PASI
PASI 75
Predictive Value of Tests
Proportional Hazards Models
Psoriasis
Psoriasis Area Severity Index
Receptors, Tumor Necrosis Factor
Registries
Retrospective Studies
Risk Assessment
Severity of Illness Index
TNF
Treatment Outcome
Tumor Necrosis Factor-alpha
Young Adult
biologics
efficacy
primary inefficacy
psoriasis
secondary loss of efficacy
switching
tumor necrosis factor
tumor necrosis factor-alfa inhibitors

Accesso al documento

10.1016/j.jaad.2013.10.019

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{f30606409dfb44d7bc727361f8f3b241,

title = "Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry",

abstract = "Some studies have shown that switching patients from one tumor necrosis factor (TNF)-alfa inhibitor to another may be beneficial when they have an inadequate response or an adverse event.",

keywords = "75% improvement in the Psoriasis Area Severity Index score, Adult, Analysis of Variance, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Cohort Studies, Confidence Intervals, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Immunoglobulin G, Italy, Male, Middle Aged, Multivariate Analysis, PASI, PASI 75, Predictive Value of Tests, Proportional Hazards Models, Psoriasis, Psoriasis Area Severity Index, Receptors, Tumor Necrosis Factor, Registries, Retrospective Studies, Risk Assessment, Severity of Illness Index, TNF, Treatment Outcome, Tumor Necrosis Factor-alpha, Young Adult, biologics, efficacy, primary inefficacy, psoriasis, secondary loss of efficacy, switching, tumor necrosis factor, tumor necrosis factor-alfa inhibitors, 75% improvement in the Psoriasis Area Severity Index score, Adult, Analysis of Variance, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Cohort Studies, Confidence Intervals, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Immunoglobulin G, Italy, Male, Middle Aged, Multivariate Analysis, PASI, PASI 75, Predictive Value of Tests, Proportional Hazards Models, Psoriasis, Psoriasis Area Severity Index, Receptors, Tumor Necrosis Factor, Registries, Retrospective Studies, Risk Assessment, Severity of Illness Index, TNF, Treatment Outcome, Tumor Necrosis Factor-alpha, Young Adult, biologics, efficacy, primary inefficacy, psoriasis, secondary loss of efficacy, switching, tumor necrosis factor, tumor necrosis factor-alfa inhibitors",

author = "Ketty Peris",

year = "2014",

doi = "10.1016/j.jaad.2013.10.019",

language = "English",

volume = "70",

pages = "257--257--62.e3",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry

AU - Peris, Ketty

PY - 2014

Y1 - 2014

N2 - Some studies have shown that switching patients from one tumor necrosis factor (TNF)-alfa inhibitor to another may be beneficial when they have an inadequate response or an adverse event.

AB - Some studies have shown that switching patients from one tumor necrosis factor (TNF)-alfa inhibitor to another may be beneficial when they have an inadequate response or an adverse event.

KW - 75% improvement in the Psoriasis Area Severity Index score

KW - Adult

KW - Analysis of Variance

KW - Antibodies, Monoclonal

KW - Antibodies, Monoclonal, Humanized

KW - Cohort Studies

KW - Confidence Intervals

KW - Dose-Response Relationship, Drug

KW - Drug Administration Schedule

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Immunoglobulin G

KW - Italy

KW - Male

KW - Middle Aged

KW - Multivariate Analysis

KW - PASI

KW - PASI 75

KW - Predictive Value of Tests

KW - Proportional Hazards Models

KW - Psoriasis

KW - Psoriasis Area Severity Index

KW - Receptors, Tumor Necrosis Factor

KW - Registries

KW - Retrospective Studies

KW - Risk Assessment

KW - Severity of Illness Index

KW - TNF

KW - Treatment Outcome

KW - Tumor Necrosis Factor-alpha

KW - Young Adult

KW - biologics

KW - efficacy

KW - primary inefficacy

KW - psoriasis

KW - secondary loss of efficacy

KW - switching

KW - tumor necrosis factor

KW - tumor necrosis factor-alfa inhibitors

KW - 75% improvement in the Psoriasis Area Severity Index score

KW - Adult

KW - Analysis of Variance

KW - Antibodies, Monoclonal

KW - Antibodies, Monoclonal, Humanized

KW - Cohort Studies

KW - Confidence Intervals

KW - Dose-Response Relationship, Drug

KW - Drug Administration Schedule

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Immunoglobulin G

KW - Italy

KW - Male

KW - Middle Aged

KW - Multivariate Analysis

KW - PASI

KW - PASI 75

KW - Predictive Value of Tests

KW - Proportional Hazards Models

KW - Psoriasis

KW - Psoriasis Area Severity Index

KW - Receptors, Tumor Necrosis Factor

KW - Registries

KW - Retrospective Studies

KW - Risk Assessment

KW - Severity of Illness Index

KW - TNF

KW - Treatment Outcome

KW - Tumor Necrosis Factor-alpha

KW - Young Adult

KW - biologics

KW - efficacy

KW - primary inefficacy

KW - psoriasis

KW - secondary loss of efficacy

KW - switching

KW - tumor necrosis factor

KW - tumor necrosis factor-alfa inhibitors

UR - http://hdl.handle.net/10807/57413

U2 - 10.1016/j.jaad.2013.10.019

DO - 10.1016/j.jaad.2013.10.019

M3 - Article

SN - 0190-9622

VL - 70

SP - 257-257-62.e3

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

ER -

Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo